• 1
    Braun M, Wassmer G, Klots T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction. Results of the ‘Cologne Male Survey’. Int J Impot Res 2000; 12: 305
  • 2
    Rosen R, O'Leary M, Altwein J, Boyle P, Giuliano F, Kirby R. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of Ageing Male (MSAM-7). Eur Urol 2003; 44: 63749
  • 3
    The Department of Veterans Affairs Cooperative Study of Transurethral Resection for Benign Prostatic Hyperplasia. A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. J Urol 1993; 150: 1696700
  • 4
    Lukacs B, McCarthy C, Grange JC. Long-term quality of life in patients with benign prostatic hypertrophy: Preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. Eur Urol 1993; 24 (Suppl. 1): 3440
  • 5
    Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol 1997; 31: 27280
  • 6
    Vallancien G, Emberton M, Harving N, Van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 2003; 169: 225761
  • 7
    McVary KT, Foley J, Bautista OM, Kusek J. Association of lower urinary tract symptoms (LUTS) with sexual function in men participating in a clinical trial of medical therapy for benign prostatic hyperplasia. J Urol 2003; 169 (Suppl.): 322
  • 8
    Sells H, Donovan J, Ewings P, MacDonagh RP. The development and validation of a quality-of-life measure to assess partner morbidity in benign prostatic enlargement. BJU Int 2000; 85: 4405
  • 9
    Brooks ST, Donovan JL, Peters TJ et al. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ 2002; 324: 105965
  • 10
    Carbone DJ, Hodges S. Medical therapy for benign prostatic hyperplasia. sexual dysfunction and impact on quality of life. Int J Impot Res 2003; 15: 299306
  • 11
    Hansen BJ, Flyger H, Brasso K et al. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS1) system for use in benign prostatic hyperplasia. Br J Urol 1995; 76: 4518
  • 12
    Schou J, Holm NR, Meyhoff HH. Sexual function in patients with symptomatic benign prostatic hyperplasia. Scand J Urol Nephrol 1996; 30 (Suppl. 179): 11922
  • 13
    Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 2001; 58: 9539
  • 14
    Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003; 92: 25761
  • 15
    Becker AJ, Uckert S, Stief CG, Scheller F, Knapp WH, Hartmann U. Cavernous and systemic plasma levels of norepinephrine and epinephrine during different penile conditions in healthy men and patients with erectile dysfunction. Urology 2002; 59: 2816
  • 16
    Traish AM, Kim NN, Goldstein I, Moreland RB. Alpha-adrenergic receptors in the penis. identification, characterization, and physiological function. J Androl 1999; 20: 67182
  • 17
    Palea S, Barras M. Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum. BJU Int 2003; 91: 8737
  • 18
    Furukawa K, Rosario DJ, Smith DJ, Chapple CR, Uchiyama T, Chess-Williams R. Alpha1A-adrenoceptor-mediated contractile responses of the human vas deferens. Br J Pharmacol 1995; 116: 160510
  • 19
    Silva MA, Megale A, Avellar MC, Porto CS. Expression and pharmacological characterization of alpha1-adrenoceptors in rat seminal vesicle. Eur J Pharmacol 1999; 381: 1419
  • 20
    Giuliano F, Bernabe J, Droupy S, Alexandre L, Allard J. A comparison of the effects of tamsulosin and alfuzosin on neurally evoked increases in bladder neck and seminal vesicle pressure in rats. BJU Int 2004; 93: 6058
  • 21
    Rouquier L, Claustre Y, Benavides J. Alpha1-adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study. Eur J Pharmacol 1994; 261: 5964
  • 22
    Lepor H, for the Tamsulosin Investigator Group. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998; 51: 892900